One of its ligands, LIGHT, otherwise known as tumor necrosis factor superfamily member 14 (TNFSF14) or CD258, could improve the effect of immunotherapy in multiple cancer models, such as lung carcinoma (16), breast carcinoma (17), cervical cancer (18), prostate cancer (19) and GBM (20). Here, TNFSF14 is linked to cervical carcinoma.